REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Effervescent Or Pressurized Fluid Containing > Organic Pressurized Fluid > Powder Or Dust Containing Powder Or Dust ContainingPowder Or Dust Containing patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070189979 - Particles The invention relates to particles for drug delivery by inhalation, said particles incorporating at least one active ingredient which is non-crystalline. The may be a plurality of active ingredients and moreover the outer surface of the particles may be substantially smooth. By providing non-crystalline particles with an outer smooth surface, ... 08/09/07 - 20070183983 - Medical composition containing nf-kb decoy for treating and preventing respir atory diseases and method of using the same A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, ... 08/02/07 - 20070178052 - Delivery of opioids through an inhalation route The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a method aspect of the present invention, an opioid is delivered to a patient through an inhalation route. The method comprises: a) heating ... 08/02/07 - 20070178051 - Sterilized nanoparticulate glucocorticosteroid formulations The invention is directed sterile to compositions of glucocorticosteroids useful in the prophylaxis and chronic treatment of asthma and other allergic and inflammatory conditions in adults and pediatric patients. ... 07/26/07 - 20070172430 - Dry powder compositions for rna influenza therapeutics A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus. ... 07/19/07 - 20070166240 - Bronchodilating beta-agonist compositions and methods Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. ... 07/19/07 - 20070166239 - Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine). ... 07/19/07 - 20070166238 - Composition and delivery system A composition for nasal or buccal application comprising a distribution of multilayer microparticles in an inactive base, at least one ingredient having activity on the mucosa of the nose/throat, being adsorbed within the layers of the microparticles so as to be progressively released over time in use; a method for ... 07/12/07 - 20070160543 - Haemostatic sprays and compositions The present invention is directed to a powder delivery system containing a composition comprising gelatine or collagen powder having a mean particle size of at least 10 μm. The gelatine or collagen powder is typically in dry form, i.e. no liquid components and/or propellants are added to the composition. The ... 07/05/07 - 20070154408 - Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of ... 07/05/07 - 20070154407 - Inhaler and store for a dry medicament formulation and related methods and use thereof An inhaler, a store and a method for atomizing a dry medicament formulation are disclosed. The medicament formulation is first dissolved by a liquid solvent and then atomized together with the solvent. This allows easy metering and satisfactory storage of the medicament formulation in the dry state. Particularly preferably, the ... 07/05/07 - 20070154406 - Spray-dried collectin compositions and process for preparing the same The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by ... 07/05/07 - 20070154405 - aerosol apparatus containing a composition for applying simultaneously several topical stimuli The invention comprises an aerosol apparatus containing a non-flammable, water-based composition, the viscosity of which composition is from 0.2 to 30 mPa·s at 20° C., which apparatus is adapted in use to release cool water-based particles for the simultaneous topical application of thermal and mechanical kinetic energy stimuli for skin ... 07/05/07 - 20070154404 - Insulin highly respirable microparticles The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the ... 06/28/07 - 20070148100 - Nanoparticulate aripiprazole formulations The present invention is directed to compositions and methods comprising nanoparticulate aripiprazole, or salts or derivatives thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect. The nanoparticulate aripiprazole compositions are proposed to have an average effective particle size of less than about 2000 nm, ... 06/21/07 - 20070140982 - Diuretic aerosols and methods of making and using them Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide, ... 06/21/07 - 20070140981 - Intranasal compositions The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a ... 06/21/07 - 20070140980 - Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is ... 06/07/07 - 20070128126 - Airway alkalinization as therapy for airway diseases The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase. ... 06/07/07 - 20070128125 - Pharmaceutical compositions based on tiotropium salts and salts of salmeterol A pharmaceutical composition, comprising: (a) a tiotropium salt (1); and (b) a salmeterol salt (2), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient, ... 06/07/07 - 20070128124 - Aerosolized capreomycin for inhibition of pulmonary tuberculosis The invention provides systems, methods, and compositions for the aerosolized administration of capreomycin to persons in need thereof. Administration of capreomycin by aerosol can be used to reduce the infectivity of persons with tuberculosis, or to reduce the severity or duration of a tuberculosis infection. The invention further provides for ... 05/31/07 - 20070122354 - Storage stable powder compositions of interleukin-4 receptor The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage. ... 05/31/07 - 20070122353 - Drug condensation aerosols and kits The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a ... 05/24/07 - 20070116650 - Device, method and use for the formation of small particles The invention relates to a device for producing small particles of a certain substance. The device includes first inlet means (4) for a solution or a suspension containing the substance and second inlet means (3) for an atomizing agent. The device further includes mixing means (12) for the solution and ... 05/17/07 - 20070110679 - Process for determining the particle size distribution of an aerosol and apparatus for carrying out such a process The measurement of the particle size distribution of an aerosol is of crucial importance in pharmaceutical development. A prerequisite for this is a valid method, e.g. the cascade impactor method described in the pharmacopoeias. It requires measurement of the active substance concentration in order to determine the particle size distribution. ... 05/17/07 - 20070110678 - Method for administration of tiotropium A method for administration and preparation of pharmaceutical dry powder doses are disclosed. The metered dry powder doses are formed from a finely divided dry powder of an selected anticholinergic agent to be used in a dry powder inhaler device. The metered dry powder medicinal dose is arranged as a ... 05/10/07 - 20070104658 - Use of simple amino acids to form porous particles Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter ... 05/10/07 - 20070104657 - Particulate compositions for pulmonary delivery This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that ... 05/10/07 - 20070104656 - Matrices formed of polymer and hydrophobic compounds for use in drug delivery A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release ... 05/10/07 - 20070104655 - Inhalable tiotropium and container therefor A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same. ... 05/10/07 - 20070104654 - Amphiphilic block copolymers and nano particles comprising the same An amphiphilic block copolymer. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nano particle and carrier comprising the amhpiphilic block copolymer for delivery of water-insoluble drugs, growth factors, genes, or cosmetic substances. ... 04/26/07 - 20070092453 - Novel crystalline forms of tiotropium bromide The invention relates to a new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. ... 04/26/07 - 20070092452 - Methods for fabrication, uses, compositions of inhalable spherical particles Inhalable spherical particles that contain an active agent having unexpectedly good bioavailability when compared to the expected bioavailability are disclosed. Inhalable spherical particles, particles of the agent that contain an amount of a cation such as zinc provide for further improvement in bioavailability. ... 04/19/07 - 20070086958 - Formation of medically useful gels comprising microporous particles and methods of use Compositions and methods use the gel-forming properties of microporous particles to create useful formulations combining two free-flowing materials to produce a hydrogel mass. The free-flowing materials preferably provide dry microporous particles (preferably as an aerosol) that may contain additional agents, and a second composition of a fluid material which is ... 04/19/07 - 20070086957 - Combination of medicaments for the treatment of respiratory diseases R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula ... 04/19/07 - 20070086956 - Method for accelerating the rate of mucociliary clearance The instant invention provides for a composition and method for using Kunitz-type serine protease inhibitors, e.g., aprotinin or bikunin, for stimulating the rate of mucociliary clearance of mucus and sputum in lung airways of subjects afflicted with mucociliary dysfunctions such as cystic fibrosis. ... 04/19/07 - 20070086955 - Form of administration for controlling primary headaches The invention relates to a nasally applied, film-shaped, bioadhesive pharmaceutical form of administration containing at least one agent-containing layer that is based on crosslinked hydrophilic polymers comprising up to 60 percent by weight of Lidocaine, the percentage being in relation to the total quantity of crosslinked hydrophilic polymers. Also disclosed ... 04/12/07 - 20070081948 - Dry powder composition comprising a benzodiazepine for pulmonary inhalation Manufacture of Pharmaceutical Compositions The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process. ... 03/29/07 - 20070071692 - Aerosol powder formulation This invention relates to dry power aerosol formulations for use with a dry powder inhaler, the formulation comprising the PDE 4 inhibitor N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide: ... 03/29/07 - 20070071691 - Composition Dry powder pharmaceutical compositions having improved storage stability, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation. ... 03/29/07 - 20070071690 - Dry powder formulations A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles ... 03/29/07 - 20070071689 - Advantageous combination for inhalation of nacystelyn and bronchodilators pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease. ... 03/22/07 - 20070065374 - Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor ... 03/22/07 - 20070065373 - Mucoactive agents for treating a pulmonary disease The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It ... 03/22/07 - 20070065372 - Process for the production of particles A process for the production of particles comprises the steps of formation of a solution of a desired substance in a suitable solvent; ii)generation of an aerosol from the solution of said substance; iii) collection of the aerosol droplets in a vessel containing a non-solvent of said substance; and iv) ... 03/22/07 - 20070065371 - Novel dry powder inhalation system for transpulmonary administration The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the present invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has: ... 03/15/07 - 20070059252 - Freeze-dried fsh/lh formulations The invention relates to the field of pharmaceutical formulations of a mixture of follicle stimulating hormone (FSH) and luteinising hormone (LH), and to methods of producing such formulations. ... 03/08/07 - 20070053846 - Dry coating and downstream processing of cohesive powders The present disclosure is directed to systems and methods for dry particle coating of cohesive powders, and to the dry coated particles/powders produced thereby. The present disclosure is further directed to systems and methods for dry coating of cohesive particles, particularly nanosized particles, to provide enhanced flowability and other advantageous ... 03/08/07 - 20070053845 - Nanocell drug delivery system Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may ... 03/08/07 - 20070053844 - Formulations for alteration of biophysical properties of mucosal lining Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may ... 03/08/07 - 20070053843 - Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and lactose anhydrate. ... 03/08/07 - 20070053842 - Method of engineering particles for use in the delivery of drugs via inhalation The present invention provides a method for engineering particles for use in the delivery of drugs via inhalation and involves the use of an artificial respiratory airway that simulates a mammalian lung system to create an environment in which particles can be engineered. The method utilizes the inhalation flow rate ... 03/01/07 - 20070048231 - Pheromone compositions and methods Compositions and methods according to the inventive subject matter make use of human pheromones, and particularly androst-16-en steroids to achieve a desired non-behavioral effect in a person exposed to such compositions. Most preferably, contemplated compositions increase exercise strength and/or stamina, and reduce airway inflammation (e.g., sinusitis). Typically, the composition is ... 03/01/07 - 20070048230 - Pheromone compositions and methods Compositions and methods according to the inventive subject matter make use of human pheromones, and particularly androst-16-en steroids to achieve a desired non-behavioral effect in a person exposed to such compositions. Most preferably, contemplated compositions increase exercise strength and/or stamina, and reduce airway inflammation (e.g., sinusitis). Typically, the composition is ... 02/22/07 - 20070041912 - Trospium containing compositions The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation ... 02/15/07 - 20070036731 - Topical delivery with a carrier fluid Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, consmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but ... 02/15/07 - 20070036730 - Cellulose derivatives Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6 ... 02/08/07 - 20070031347 - Powdered medicaments containing a tiotropium salt and salmeterol xinafoate The invention relates to powdered preparations for inhalation containing a tiotropium salt and salmeterol xinafoate, processes for preparing them and their use in the preparation of a pharmaceutical composition for treating respiratory diseases, particularly for treating COPD (chronic obstructive pulmonary disease) and asthma. ... 02/01/07 - 20070025923 - Use of ciclesonide for the treatment of respiratory diseases The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children. ... 01/25/07 - 20070020199 - Dispersible macromolecule compositions and methods for their preparation and use A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly ... 01/25/07 - 20070020198 - Medical product containing tiotropium The invention discloses a medical product that may be used in a treatment of respiratory disorders. ... 01/25/07 - 20070020197 - Preparation of pharmaceutical compositions containing nanoparticles Materials and methods for preparing pharmaceutical nanoparticle suspensions or dispersions, granulations and dosage forms are disclosed. The methods employ a modular high-pressure spray homogenizer coupled to a wet granulator to form stabilized nanoparticle suspensions and granulations. ... 01/18/07 - 20070014738 - Particles for inhalation having sustained release properties The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of ... 01/18/07 - 20070014737 - Delivery of muscle relaxants through an inhalation route The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method ... 01/11/07 - 20070009445 - Aerosol compositions and methods The present invention provides drug formulations and methods that comprise omega-3 and/or omega-6 fatty acids, and their ester derivatives (e.g., methyl, ethyl, isopropyl, etc.), which are soluble in non-CFC propellants. The addition of omega-3 or omega-6 fatty acids to the aerosol formulations also provides therapeutic benefits. ... 01/11/07 - 20070009444 - Method for preparing powder exhibiting low susceptibility to electrification A method of producing lowly-charged powder comprising drying a liquid composition containing a highly-charged compound and polyethyleneglycol. ... 01/04/07 - 20070003487 - Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions A pharmaceutical composition, constituting a spray suspension includes at least one liquid excipient and at least one solid excipient substantially insoluble in the liquid excipient, and at least one pharmaceutical active ingredient. A method of preparing porous suspension particles includes: a) wet-milling or dry-milling the solid excipient(s) or a mixture ... 12/28/06 - 20060292085 - Medicaments There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There ... 12/28/06 - 20060292084 - Process for cleaning hard gelatine capsules A process which can be used in the laboratory or on an industrial scale for cleaning the inner wall of hard gelatine capsules, in which the sealed capsules are cleaned with a powder formulation. ... 12/28/06 - 20060292083 - Inhalation compositions with high drug ratios The invention provides a dry powder inhalation composition comprising, at least 0.25% by weight of the composition of an active ingredient with a particle size of less than 10 microns in diameter and a pharmaceutically acceptable particulate carrier with a particle size of less than 250 microns in diameter. Also ... 12/28/06 - 20060292082 - Dry powder inhaler A dry powder inhaler for delivering a dose of medicament for inhalation by a user, including a drug entrainment device and a valve actuable by a user to cause pressurised gas to flow through a dose of medicament disposed in the drug entrainment device to entrain said dose in the ... 12/28/06 - 20060292081 - Methods for preparing pharmaceutical compositions The present invention relates to improvements in dry powder formulations comprising a pharmaceutically active agent for administration by inhalation, and in particular to methods of preparing dry powder compositions with improved properties. In particular, spray drying processes are adapted and adjusted to obtain active particles with higher fine particle fractions ... 12/21/06 - 20060286043 - Delivery of antihistamines through an inhalation route The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a method aspect of the present invention, an antihistamine is delivered to a patient through an inhalation route. The method comprises: a) heating ... 12/21/06 - 20060286042 - Delivery of sedative-hypnotics through an inhalation route The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hypnotic drug is administered to a patient through an inhalation route. The method comprises: a) ... 12/21/06 - 20060286041 - Mrp iv inhibitors for the treatment of respiratory diseases The present invention relates to the use of MRP4 inhibitors for the treatment of respiratory diseases, pharmaceutical compositions containing them and processes for the preparation thereof. ... 12/21/06 - 20060286040 - Medicament compositions comprising a heterocyclic compound and an anticholinergic The present invention relates to novel pharmaceutical compositions based on anticholinergics of the formula 1; wherein X−, R1 ? and Ar are defined as in claim 1, and a heterocyclic compound of the formula 2. Furthermore, the invention relates to processes for preparing them and their use in the treatment ... 12/14/06 - 20060280692 - Delivery of antipsychotics through an inhalation route The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating ... 12/14/06 - 20060280691 - Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery A powder for inhalatory aerosol delivery, the powder having: spray freeze dried liposome particles with a biologically active agent, such as an antibiotic, encapsulated within a phospholipid, and a method of producing a powder for inhalatory aerosol delivery, the method including the steps of: mixing a biologically active agent with ... 12/07/06 - 20060275219 - Radial spherical crystallization product, process for producing the same, and dry powder preparation containing the crystallization product A radial spherical crystallization product having multiple needle-shaped projections radially extending outward from the core portion. The radial spherical crystallization product is produced by, for example, bringing a supercritical fluid mixed with a modifier according to necessity and a solution containing a sample component, which have been introduced through different ... 11/30/06 - 20060269487 - Delivery of nonsteroidal antiinflammatory drugs through an inhalation route The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention, an NSAID is delivered to a patient through an inhalation route. The method ... 11/30/06 - 20060269486 - Delivery of diazepam through an inhalation route The present invention relates to the delivery of compounds for the treatment of anxiety disorders and symptoms of such disorders through an inhalation route. Specifically, it relates to aerosols containing diazepam that are used in inhalation therapy. In a method aspect of the present invention, diazepam is administered to a ... 11/16/06 - 20060257330 - Powdery pharmaceutical compositions for inhalation Powdery pharmaceutical compositions including an active ingredient and carrier particles containing only a small amount of lubricant, 0.05-0.5% by weight, are used to prepare dry powder inhalers in order to increase the fine particle dose. A process for coating the surface of the carrier particles with such little amount of ... 11/16/06 - 20060257329 - Delivery of drug esters through an inhalation route The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a method aspect of the present invention, a drug ester is delivered to a patient through an inhalation route. The method ... 11/16/06 - 20060257328 - Delivery of caffeine through an inhalation route The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of caffeine. In a method ... 11/16/06 - 20060257327 - Medical product The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into ... 11/16/06 - 20060257326 - Methods and formulations for delivery of pharmacologically active agents In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material. ... 11/09/06 - 20060251589 - Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) ... 11/09/06 - 20060251588 - Delivery of erectile dysfunction drugs through an inhalation route The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a method aspect of the present invention, an erectile dysfunction drug is delivered to a patient through an inhalation ... 11/09/06 - 20060251587 - Delivery of analgesics through an inhalation route The present invention relates to the delivery of analgesics through an inhalation route. Specifically, it relates to aerosols containing acetaminophen, orphenadrine or tramadol that are used in inhalation therapy. In a method aspect of the present invention, an analgesic is administered to a patient through an inhalation route. The method ... 11/09/06 - 20060251586 - Method for the administration of an anticholinergic by inhalation An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of ... 11/09/06 - 20060251585 - Compositon useful for delivery of active agents The invention provides a safe drug delivery composition that enhances the absolute bioavailability of active agent (drug). ... 11/09/06 - 20060251584 - Drug nano-particle, method and apparatus for preparing pharmaceutical preparation using the particle This invention provides a drug nanoparticle 7 obtained by irradiating laser beam 3 to a solid target 2 composed of drug powder so as to release the drug as downsized component particle from the solid target 2, wherein the drug nanoparticles 7 has an average diameter of 100 nm or ... 11/02/06 - 20060246012 - Delivery of physiologically active compounds through an inhalation route The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a method aspect of the present invention, the physiologically active compound is delivered to a patient through an inhalation ... 11/02/06 - 20060246011 - Delivery of diphenhydramine through an inhalation route The present invention relates to the delivery of diphenhydramine through an inhalation route. In a composition aspect of the present invention, a composition of a diphenhydramine condensation aerosol is presented. In a method aspect of the present invention, diphenhydramine aerosol is formed by: a) heating a thin layer of diphenhydramine ... 11/02/06 - 20060246010 - Process for determining the particle size distribution of an aerosol and apparatus for carrying out such a process The present invention provides, for the first time, a process that meets the needs of the drug industry for measuring the particle size of nebulised aerosols simultaneously or one after another by the laser diffraction method and the cascade impactor method which is known in the art. In this way ... 11/02/06 - 20060246009 - Novel crystalline forms of tiotropium bromide The invention relates to new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. ... 10/26/06 - 20060239936 - Delivery of anti-migraine compounds through an inhalation route The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a ... 10/26/06 - 20060239935 - Compositions for inhalation wherein the groups R1, R2, R3 and R4 may have the meanings given in the specification and in the claims, processes for preparing them and their use in the treatment of respiratory complaints. ... 10/26/06 - 20060239934 - Superior control of blood glucose in diabetes treatment Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. ... 10/26/06 - 20060239933 - Medical product A medical product is disclosed. The medical product contains an accurately metered dose of at least one GLP medicament intended for pulmonary inhalation put into a moisture-tight, high barrier seal container. The medical product optionally also contains a dose of insulin. The container is adapted for application into a dry ... 10/26/06 - 20060239932 - Pharmaceutical formulations comprising magnesium stearate The invention relates to the use of magnesium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active ... 10/26/06 - 20060239931 - Pharmaceutical aerosol composition An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered. Nebulizers and inhalers containing such formulations are also described and claimed. ... 10/19/06 - 20060233719 - Delivery of antidepressants through an inhalation route The present invention relates to the delivery of antidepressants through an inhalation route. Specifically, it relates to aerosols containing an antidepressant that are used in inhalation therapy. In a method aspect of the present invention, an antidepressant is administered to a patient through an inhalation route. The method comprises: a) ... 10/19/06 - 20060233718 - Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route The present invention relates to aerosols containing alprazolam, estazolam, midazolam or triazolam that are used in inhalation therapy. In a method aspect of the present invention, alprazolam, estazolam, midazolam or triazolam is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of alprazolam, ... 10/19/06 - 20060233717 - Delivery of compounds for the treatment of headache through an inhalation route The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy. ... 10/19/06 - 20060233716 - Pharmaceutical formulations The invention relates to the use of a ternary agent that is a sugar ester to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier and the ternary ... 10/19/06 - 20060233715 - Compositions for nasal administration of drug Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals. ... 10/05/06 - 20060222599 - Inhalative powder formulations containing the cgrp-antagonist 1 [n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine Powdered preparations for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a pharmaceutically acceptable salt thereof, processes for preparing them and the use thereof for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache. ... 09/28/06 - 20060216244 - Delivery of compounds for the treatment of parkinson's through an inhalation route The present invention relates to the delivery of antiparkinsons drugs through an inhalation route. In a method aspect of the present invention, an antiparkinsons drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiparkinsons drug on a solid support ... 09/28/06 - 20060216243 - Delivery of beta-blockers through an inhalation route The present invention relates to aerosols containing of atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a method aspect of the present invention, of atenolol, pindolol, esmolol, propranolol, or metoprolol is administered to a patient through an inhalation route. The method comprises: a) heating a ... 09/21/06 - 20060210485 - Pharmaceutical formulations The invention relates to the use of calcium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active ... 09/14/06 - 20060204450 - Pharmaceutical compositions based on anticholinergics and pde 5-inhibitors The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE 5-inhibitors, processes for preparing them and their use in the treatment of pulmonary hypertension. ... 09/14/06 - 20060204449 - Nasal pharmaceutical composition of piribedil The present invention relates to a pharmaceutical composition for the administration, by the nasal route, of piribedil in solution or in powder form. ... 09/14/06 - 20060204448 - Powdery preparation for nasal administration According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided. ... 08/31/06 - 20060193788 - Acute treatment of headache with phenothiazine antipsychotics Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic. ... 08/31/06 - 20060193787 - Nanoparticle-based drug delivery system A drug delivery system based on at least one type of nanoparticle. In particular, a nanoparticle-based drug delivery system including at least one first drug, at least one second drug and at least one type of nanoparticle. ... 08/24/06 - 20060188451 - Aerogel based pharmaceutical formulations Drugs in the form of very fine highly porous aerogel particles are delivered to a patient via inhalation. The aerogel particles are either an aerogelized form of a pharmaceutical or deposited upon aerogel particles produced from a non-inorganic oxide carrier matrix material, e.g. a sugar or carbohydrate. The aerogel particles ... 08/17/06 - 20060182692 - Chemically modified small molecules Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a ... 08/17/06 - 20060182691 - Impregnated powder improving bioavailability and/or the solubility and method of production This invention relates to an impregnated powder for increasing the bioavailabilty and/or the solubility of at least one active principle comprising a solid, inert support in a particle form impregnated by a liquid medium comprising a hydrophobic phase and optionally a hydrophilic phase, at least one surfactant and at least ... 08/10/06 - 20060177382 - Delivery of antiemetics through an inhalation route The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating ... 08/03/06 - 20060171899 - Water-stabilized aerosol formulation system and method of making The invention relates to an aerosol formulation system comprising a primary package system and an aerosol formulation therein wherein the aerosol formulation comprises insulin, a propellant and an amount of water sufficient to reach equilibrium quantities based on the moisture sorption rate diffusing across the primary package system in which ... 07/27/06 - 20060165606 - Pulmonary delivery particles comprising water insoluble or crystalline active agents A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the ... 07/27/06 - 20060165605 - Process to regenerate fcc spent catalyst A process to supply solid particles to a fluidized bed via a riser which has a substantially vertical upper part terminating at an outlet opening in the fluidized bed and wherein the solid particles are transported towards the fluidized bed in the riser with a lift gas, which lift gas ... 07/20/06 - 20060159629 - Pulmonary delivery particles with phospholipid structural matrix A pulmonary delivery medicament comprises a plurality of particulates, each particulate having a perforated microstructure comprising a phospholipid structural matrix and active agent, the phospholipid structural matrix comprising greater than about 50% w/w phospholipid, and the particulates having a geometric diameter of from 0.5 to 50 μm. The medicament can ... 07/20/06 - 20060159628 - Nanoparticulate benzothiophene formulations The present invention is directed to benzothiophene compositions, preferably nanoparticulate raloxifene hydrochloride compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the raloxifene hydrochloride nanoparticulate composition have an effective average particle size of less than about 2000 nm. ... 07/13/06 - 20060153779 - Delivery of stimulants through an inhalation route The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a patient through an inhalation route. The method comprises: a) heating ... 07/13/06 - 20060153778 - Methods and compositions for minimizing accrual of inhalable insulin in the lungs Inhalable insulin compositions are provided that rapidly clear from the lungs of patients. Additionally, methods of minimizing insulin accrual after administration of an inhaled insulin composition are disclosed. ... 07/06/06 - 20060147389 - Devices and pharmaceutical compositions for enhancing dosing efficiency The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently ... 07/06/06 - 20060147388 - Pharmaceutical compositions for nasal delivery According to the invention there is provided a powdered pharmaceutical formulation suitable for nasal delivery which is a freeze-dried blend of active material and excipient(s) containing: 0.5-50% by wt of active material 50-99.5% by wt of excipient(s), and in which at least 0.1% by wt of the blend is an ... 07/06/06 - 20060147387 - Process to minimize loss through adhesion to equipment surfaces The invention relates to a new process for preparing combination formulations of inhaled glucocorticoids and beta 2-agonists e.g. budesonide in combination with formoterol. The process aims at minimizing adhesion of one or more of the ingredients to equipment surfaces by adding the ingredients to a container in a stepwise manner. ... 06/29/06 - 20060140875 - Semi-soft c-class immunostimulatory oligonucleotides The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C. ... 06/29/06 - 20060140874 - Stable aerosol formulations of peptides and protein with non-cfc propellants Glycosidicaily stabilised macromolecules, such as proteins and peptides, have substantially greater stability in the presence of hydrofluoroalkane propellants for dispensing from metered dose inhalers, when formulated with polyhydroxylated polyalkenes such as PVA. ... 06/22/06 - 20060134010 - Chemical composition and process The invention concerns an aqueous slurry comprising thermally expandable microspheres comprising a thermoplastic polymer shell and a propellant entrapped therein, said slurry further comprising an at least partially water soluble polymer selected from the group consisting of gums, celluloses, chitins, chitosans, glycans, galactans, pectins, mannans, dextrins, polyacrylic acid, esters and ... 06/22/06 - 20060134009 - Low dose corticosteroid powders for inhalation The invention relates to a method of treating a corticosteroid-responsive condition of the air passage ways and lungs by delivering a corticosteroid to the pulmonary system of a patient, comprising administering a particle mass comprising a corticosteroid from an inhaler characterized in that the corticosteroid is not substantially deposited in ... 06/22/06 - 20060134008 - Compositions and methods for pulmonary conditions Compositions and methods for the treatment of pulmonary conditions, especially pulmonary conditions characterized by persistent cough, are disclosed. The compositions and methods employ at least one muscarinic receptor antagonists and at least one local anesthetic administered pulmonarily either simultaneously or in sequence. The compositions may be in powder or liquid ... 06/22/06 - 20060134007 - Blister for inhalers The invention relates to a blister for charging an inhaler with a pharmaceutical preparation, characterised in that the blister is at least partially manufactured from a dehydrating plastics material. The invention also relates to blisters according to the invention which are filled with a pharmaceutical preparation. ... 06/15/06 - 20060127323 - Formoterol and ciclesonide combination The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease. ... 06/08/06 - 20060120973 - Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone. ... 06/08/06 - 20060120972 - 9-(n-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension Pimethixene is used as a medicament for the treatment of pulmonary hypertension. ... 06/08/06 - 20060120971 - Agents and methods for administration to the central nervous system The present invention provides pharmaceutical compositions and methods for intranasal administration to a subject to increase long-chain acyl CoA levels in the CNS (e.g., the hypothalamus), to reduce food intake and/or reduce appetite, to improve hepatic autoregulation, and/or to treat a metabolic disorder such as diabetes mellitus, metabolic syndrome, hyperglycemia, ... 06/08/06 - 20060120970 - Surface modification of lactose excipient for use in powders for inhalation The invention relates to a process for the surface-energy passivation of lactose which is intended for use as an excipient in the production of inhalable powders, and the use of such optimised carrier materials in the manufacture of inhalable powders. ... 06/08/06 - 20060120969 - Medical product for inhalation containing glucagon-like peptide-1 (glp-1) A medical product containing an accurately metered dose of a GLP-1 medicament intended for pulmonary inhalation put into a moisture-tight, high barrier seal container. The medical product optionally also contains a dose of insulin. The container is preferably adapted for application into a dry powder inhaler. The dose loaded in ... 06/01/06 - 20060115432 - New powdered inhalants based on modified lactose mixtures as excipient The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention. ... 05/25/06 - 20060110333 - Composition for nasal absorption This invention attempts to provide a composition for intranasal administration which has markedly lower risk of developing side effects compared to oral formulation, which promptly exhibits analgesic effects, and which has excellent bioavailability. The composition for nasal absorption comprises a carrier of calcium carbonate and/or calcium phosphate having an average ... 05/25/06 - 20060110332 - Agent for medicamentous treatment of acute and chronic pain The invention relates to an agent for the medicamentous treatment of acute and chronic pain, in particular of allodynia and hyperalgesia. Fields of application of the invention are medice and the pharmaceutical industry. A new pharmaceutical composition for the treatment of acute and/or chronic pain, in particular allodynia and hyperalgesiais ... 05/18/06 - 20060104917 - Stable pharmaceutical products Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide. ... 05/18/06 - 20060104916 - Method and apparatus for enhanced size reduction of particles The present invention provides methods and apparatus for producing particles via supercritical fluid processing. In one embodiment, the method includes expanding a supercritical fluid plasticized melt across a pressure drop to form solid composite particles that are simultaneously dispersed, foamed and cooled, and milling the solid particles produced to achieve ... 05/18/06 - 20060104915 - Aerosol dentifrice formulation An aerosol dentifrice formulation is provided comprising a high water based system, a specific particle size abrasive and a liquified gas propellant, characterised in that the liquified gas comprises 2-8 wt % of a non-hydrocarbon and 2-6 wt % of a hydrocarbon propellant. There is provided a dentifrice formulation comprising ... 05/11/06 - 20060099150 - Compositions and methods for the transport of biologically active agents across cellular barriers Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active portion and a targeting element directed to a ligand ... 05/04/06 - 20060093557 - Particulate composition Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with ... 05/04/06 - 20060093556 - Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially ... 04/27/06 - 20060088479 - Particle formulation and its preparation Powder compositions are prepared which compose microparticles having a bioactive agent dispersed therein. The compositions are prepared by spray drying a solution or suspension of the bioactive and collecting the resulting microparticles using a separator. ... 04/20/06 - 20060083694 - Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same. A flowing aerosol is generated that includes droplets of a precursor medium dispersed in a gas phase. The precursor medium contains a liquid vehicle and at least one precursor. At least a portion ... 04/06/06 - 20060073105 - Novel dry powder inhalation system for transpulmonary administration The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the present invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has: ... 03/30/06 - 20060067892 - Topical nanoparticulate spironolactone formulation The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar ... 03/30/06 - 20060067891 - Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin A metered dose spray device administers medicine contained therein to the buccal cavity within a user's mouth upon actuation of the device. A metered dose spray device comprising an insulin solution is also provided. ... 03/23/06 - 20060062741 - Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis. ... 03/23/06 - 20060062740 - Capsule for a powder medicament A capsule for a powder has a body which is provided with an internal chamber (21) to hold the powder and first and second openings to an exterior environment. The body is adapted to be displaced from a filling state, in which the first and second openings are placed in ... 03/16/06 - 20060057074 - Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases. ... 03/09/06 - 20060051300 - Formulations and methods for treating rhinosinusitis The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent. ... 03/09/06 - 20060051299 - Nasal pharmaceutical formulations and methods of using the same Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific ... 03/02/06 - 20060045850 - Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids Aqueous, anti-inflammatory steroid compositions in solution form suitable for nasal administration and having a reduced stinging sensation are provided as well as a method for treating inflammation of the nasal mucosa by intranasal administration of anti-inflammatory steroid compositions. These solution compositions may result in enhanced nasal bio-availability. The anti-inflammatory steroid ... 02/23/06 - 20060039871 - Nasal pharmaceutical formulations and methods of using the same Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific ... 02/23/06 - 20060039870 - Pulmonary delivery of enzymatic medical countermeasures The present invention provides for non-invasive treatment of nerve agent poisoning by administering nerve agent neutralizing enzymes to the pulmonary epithelium of a subject, by inhalation, where they accumulate within the lungs. Localization of such enzymes in the pulmonary epithelium results in neutralization of the nerve agents at the lungs. ... 02/23/06 - 20060039869 - Intranasal delivery of antipsychotic drugs An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug ... 02/16/06 - 20060034777 - Safe removal of volatile oxidizable compounds from particles, in particular polymer particles In a method of removing volatile oxidizable compounds from particles present in a container, a gas stream is continuously introduced into the container, the gas stream takes up the oxidizable compound from the particles in the container and a gas stream laden with the oxidizable compound is discharged from the ... 02/09/06 - 20060029552 - Carrier particles for use in dry powder inhalers A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the ... 02/09/06 - 20060029551 - Stable particle formulations of erythropoietin receptor agonists A particle formulation includes an erythropoietin receptor agonist, a buffer, and a sugar, wherein the buffer and sugar stabilize the erythropoietin receptor agonist against aggregation. ... 02/02/06 - 20060024242 - Solubilizing liquid of refractory element and producing method thereof A method for solubilizing in water a refractory element not soluble in water can be a method of adding a refractory element to material water obtained by solving a solubilizer, and finely grinding the refractory element using a homogenizer. However, the mechanical method of grinding using a homogenizer cannot evenly ... 02/02/06 - 20060024241 - Vitamin b12 compositions The present invention provides improved vitamin B12 compositions containing a mixture of vitamin B12 analogues that are better absorbed into the bloodstream of a patient with vitamin B12 deficiency, preferably via their mucosal membranes and also discusses convenient and inexpensive delivery methods for these compositions without the discomfort of subcutaneous ... 02/02/06 - 20060024240 - Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are ... 01/26/06 - 20060018841 - Aav vectors for gene delivery to the lung Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue. ... 01/12/06 - 20060008421 - Pharmaceutical combination The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) an adrenergic β2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease. ... 01/05/06 - 20060002864 - Milling process for the production of finely milled medicinal substances The present invention is a method of milling materials to form a fine powder with a median particle size below 10 micrometer which is suitable for inhalation and which has substantially no amorphous content generated during milling. The method is particularly suitable for milling materials which are soft. The method ... 01/05/06 - 20060002863 - Aerosol suspension formulations containing tg 227 ea or tg 134 a as propellant Disclosed are propellant gas formulations containing at least one suspended active substance which contains chemically bound water, water and the propellant TG 227 or TG 134 a. ... 01/05/06 - 20060002862 - High pressure spray-dry of bioactive materials This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents, organic solvents, and/or surfactants. Formulations are provided for spraying therapeutic bioactive materials into powder particles containing amino ... 01/05/06 - 20060002861 - Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist or a solvate thereof, in combination with a muscarinic receptor antagonist. ... 12/29/05 - 20050287080 - Use of mometasone furoate for treating airway passage and lung disease The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed. ... 12/29/05 - 20050287079 - Combinations of formoterol and fluticasone propionate for asthma A pharmaceutical composition comprising (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) fluticasone propionate, suitable for use in the treatment of inflammatory or obstructive airways diseases. ... 12/29/05 - 20050287078 - Minimizing powder retention on surfaces The invention relates to a method for improving the powder output, i.e. the emitted medication dose, from a dry powder inhaler device by minimizing the powder retention inside the device. Also therapeutic efficacy of the metered medication dose is hereby improved. It is found that adding a smaller amount of ... 12/29/05 - 20050287077 - Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon The present invention relates to processes for preparing a stable sol of medicament and hydrofluorocarbon, and for preparing medicament delivery devices containing said sol. This invention also relates to a sol composition resulting from said process. This invention further relates to apparatuses for preparing said medicament delivery devices. ... 12/29/05 - 20050287076 - Compounds for use as surfactants and uses of such compounds are described. ... 12/15/05 - 20050276759 - Solid dose delivery vehicle and methods of making same The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing ... 12/08/05 - 20050271597 - Prostate hypertrophy treatment composition and method The present invention provides a method and composition for treatment of benign prostate hyperplasia (BPH) in men via a transscrotal delivery system. The composition of the present invention includes the steroid hormone progesterone containing permeation enhancers that greatly facilitate permeation through the skin, thus preventing modification of the constituents therein ... 12/01/05 - 20050265928 - Pulmonary malarial vaccine Particulate compositions for delivery, preferably pulmonary, which provide sustained release of antigens, preferably DNA and/or peptide and/or protein antigens, have been developed. In the preferred embodiment, aggregate nanoparticles are in the aerodynamic range of 1-5 microns diameter and fly deep into the lungs. As the aggregate particles degrade in the ... 12/01/05 - 20050265927 - Intranasal delivery of nucleic acid molecules Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery ... 11/24/05 - 20050260140 - Mucolytic and anti-elastase compounds and methods of use thereof Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. Also disclosed are compositions and methods for inhibiting elastase in a patient. The compositions contains a compound containing a dithiol active-site in reduced state ... 11/24/05 - 20050260139 - Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists The present invention relates to novel pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists, processes for preparing them and their use in the treatment of respiratory diseases. ... 11/17/05 - 20050255051 - Formulation for inhalation Microparticles, obtainable by spray-drying a substantially pure solution of a therapeutic agent, consist essentially of the agent having its therapeutic activity when administered to the lung. In a preferred embodiment the agent is insulin. ... 11/17/05 - 20050255050 - Powder formulations for inhalation, comprising enantiomerically pure beta agonists wherein the groups R1, R2, R3 and R4 may have the meanings given in the claims and in the specification, optionally in the form of the pharmaceutically acceptable acid addition salts thereof, as well as optionally in combination with a pharmaceutically acceptable excipient, processes for preparing them and their use ... 11/17/05 - 20050255049 - Formoterol and mometasone aerosol formulations A pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, ... 11/10/05 - 20050249676 - Pullulan capsules The invention is a hard capsule comprising pullulan in an amount of 85% to 90% by weight, potassium chloride in an amount of 1.0% to 1.5% by weight, carrageenan in an amount of 0.1% to 0.4% by weight, one or more surfactants in an amount of 0.1% to 0.2% by ... 11/10/05 - 20050249675 - Mucin synthesis inhibitors The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. ... 11/10/05 - 20050249674 - Aerosol composition An aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 μm, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to ... 11/03/05 - 20050244341 - Aerodynamically light particles for pulmonary drug delivery Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 μm ... 11/03/05 - 20050244340 - Dry powder compositions Dry powder pharmaceutical compositions having improved storage stability, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation. ... 10/27/05 - 20050238588 - Process for determining the particle size distribution of an aerosol and apparatus for carrying out such a process The present invention provides, for the first time, a process that meets the needs of the drug industry for measuring the particle size of nebulised aerosols simultaneously or one after another by the laser diffraction method and the cascade impactor method which is known in the art. In this way ... 10/20/05 - 20050232873 - Aerosol formulation containing particulate formoterol, propellant and polar cosolvent A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of ... 10/13/05 - 20050226818 - Anticholinergic powder formulations for inhalation wherein X− is a pharmaceutically acceptable anion; and (b) a physiologically acceptable excipient having an average particle size of 10 μm to 50 μm, processes for preparing the inhalable powder, and methods of administration for the treatment of respiratory complaints, particularly for the treatment of chronic obstructive pulmonary disease (COPD) ... 10/06/05 - 20050220722 - Method of decreasing fasting sugars and weight gains in diabetic patients Inhaled insulin, relative to subcutaneously and/or transdermally administered insulin, can be used to prevent the rate of weight gain and to lower the levels of fasting glucose in diabetic patients. ... 10/06/05 - 20050220721 - Anti-adhesion spraying Dry powders containing bioresorbable hyaluraonic acid (“HA”) are applied directly to a desired location in a patient wound to reduce adhesions, without first forming a hydrated gel. HA includes hyaluronic acid that has been modified, cross-linked or combined with other substances. It is important to control the size of the ... 10/06/05 - 20050220720 - Formulations limiting spread of pulmonary infections Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as ... 09/29/05 - 20050214228 - Process for producing fine medicinal substance A method of producing fine medicament particles suitable for inhalation, particles produced by the method and apparatus suitable for carrying out the method. The method comprises contacting a stream or streams of a solution of medicament with a stream or streams of a liquid in which the medicament is insoluble ... 09/29/05 - 20050214227 - Microparticle formulations for sustained-release of bioactive compounds A composition is provided for administration to a subject by way of a needleless syringe. The composition is formed from particles having a mean mass aerodynamic diameter of from 1 to 250 microns, and an envelope density of from 0.1 to 25 g/cm3, where the particles include a biologically active ... 09/29/05 - 20050214226 - Method of producing hollow, microporous particles which are intended, in particular to be inhaled The invention relates to a method of producing hollow, microporous particles which are intended, in particular, to be inhaled or for any other application. The inventive method consists in: providing a composition, in a given form, comprising at least one active principle and at least one blowing agent; cooling the ... 09/22/05 - 20050207991 - Aerosol formulations containing p134a and particulate medicament A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an a |